AI Article Synopsis
- Unfractionated heparin (UFH) is used to prevent and treat blood clots, with dosages typically based on weight, but the study aimed to compare the effectiveness of fully weight-based dosages to non-weight-based titrations after a protocol change in 2019.
- The study was a retrospective, observational analysis comparing two groups of patients: one treated under the previous fully weight-based protocol (2015-2016) and another under the newer non-weight-based protocol (2020).
- Results showed similar effectiveness in achieving the desired anticoagulation levels, with both groups needing a median of one dosage adjustment; however, the fully weight-based group had a slightly higher rate
Article Abstract
Background: Unfractionated heparin (UFH) is used for the prevention and treatment of arterial or venous thromboembolism. The dosage for IV infusion of UFH is generally based on the patient's weight, with adjustment to a specific target for activated partial thromboplastin time (aPTT). In May 2019, the UFH protocols at the study institution were changed from being fully weight-based (i.e., for both initial dosing and subsequent dosage titrations) to weight-based initial dosing and non-weight-based dosage titrations, but the relative effectiveness of these 2 approaches was not known.
Objectives: The primary objective was to compare the effectiveness in achieving therapeutic aPTT with the fully weight-based and non-weight-based dosage titration protocols. The secondary objective was to compare the effectiveness of the non-weight-based dosage titration protocol with that of the previous fully weight-based one for patients with low-target aPTT.
Methods: A single-centre, retrospective, observational before-and-after study was conducted for patients receiving therapeutic UFH for any indication. Patients in the "before" group (fully weight-based protocol) were treated from January 2015 to October 2016, and those in the "after" group (non-weight-based titration) from January to October 2020.
Results: From a total of 1969 charts screened, 137 patients treated according to the fully weight-based protocols and 130 patients treated according to the non-weight-based titration protocols were included. In terms of the co-primary objective, the median number of dosage adjustments to achieve therapeutic anticoagulation was 1 in both groups ( = 0.48), and the proportion of patients with therapeutic anticoagulation at 24 h was similar (96.2% [125/130] with the non-weight-based titration protocols versus 99.3% [136/137] with the fully weight-based protocols; = 0.09). Among patients treated according to the low-target UFH protocols, those with the non-weight-based titration protocol were less likely to have therapeutic anticoagulation at first measurement of aPTT than those with the fully weight-based protocol (37.9% [25/66] versus 44.6% [41/92], = 0.033).
Conclusions: This retrospective, observational, before-and-after study showed that the effectiveness of the non-weight-based dosage titration protocols in achieving therapeutic aPTT was similar to that of fully weight-based UFH protocols.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817222 | PMC |
| http://dx.doi.org/10.4212/cjhp.3265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population Pharmacokinetics of Ledipasvir/Sofosbuvir in Pediatric Patients: Impact of Acute Lymphoblastic Leukemia.
Clin Ther
December 2024
Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Purpose: The pharmacokinetic (PK) profile of direct-acting antivirals, namely ledipasvir/sofosbuvir (LDV/SOF), might be altered in patients with acute lymphoblastic leukemia (ALL), affecting the optimum dose needed for hepatitis C virus treatment. Limited data are available evaluating the population PK of LDV/SOF and SOF metabolite GS-331007. We aimed to study whether ALL could affect population PK parameters of LDV, SOF, and the SOF major metabolite GS-331007 in hepatitis C virus-infected children, develop and validate a predictive PK model of LDV/SOF disposition in this special population, and identify their explained and unexplained sources of variability.
View Article and Find Full Text PDFDevelopment and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A.
Thromb Res
October 2023
Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 10045, China. Electronic address:
Background: As the most commonly used coagulation factor VIII (FVIII) concentrate in China, the individualized dosing prediction model of Kovaltry (BAY81-8973) is not fully investigated in pediatric patients. The prophylaxis tailored by population pharmacokinetic (PopPK) model can optimize dosing regimens.
Objectives: This study aimed to develop PopPK models of BAY 81-8973 in pediatric patients, identify quantitative relationships of blood type (as a substitution for von Willebrand factor) on FVIII clearance and provide model-informed precision dosing (MIPD) procedures.
Behavioral Weight Management Interventions for Hispanic Men in the United States: A Systematic Review.
Am J Mens Health
October 2024
Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.
Article Synopsis
- Hispanic men have the highest obesity rates but are often overlooked in weight management programs; a systematic review highlights this issue.
- The review analyzed 12 interventions from over 6,500 studies, primarily from the last decade, focusing on behavioral strategies tailored for Hispanic men.
- Despite most studies lacking robust randomized controls, the findings suggest some efficacy in short-term weight loss, stressing the need for more well-designed trials that cater specifically to this demographic.
Sun-protection factor of zinc-oxide sunscreens: SPF too low compared to SPF-a brief review.
Photochem Photobiol Sci
October 2024
Uviva Technologies GmbH, Duisburg, Germany.
Sunscreens are mainly characterized by their sun-protection factor (SPF), which is measured according to the in vivo gold standard ISO 24444. Although the SPF concept is simple, SPF values are difficult to measure, due to the rather high variability caused by the complex interaction of light and skin. For half a century, there have been attempts to correlate the costly and ethically controversial in vivo procedure with a non-invasive (in vitro) method.
View Article and Find Full Text PDFPopulation Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2.
Pharm Res
October 2024
Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
Article Synopsis
- Casirivimab (CAS) and imdevimab (IMD) are monoclonal antibodies designed to treat and prevent SARS-CoV-2 infections by blocking the virus's ability to enter host cells.
- A pharmacokinetic analysis using data from 7 clinical studies involving 7598 individuals helped assess how the drugs behave in the body and what factors might influence their effectiveness.
- The study found that body weight and serum albumin significantly impact drug levels, leading to insights that will help determine appropriate dosages for both pediatric and adult patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!